These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16195922)

  • 1. A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations.
    Nikolaou M; Tam VH
    J Math Biol; 2006 Feb; 52(2):154-82. PubMed ID: 16195922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical modelling response of Pseudomonas aeruginosa to meropenem.
    Tam VH; Schilling AN; Poole K; Nikolaou M
    J Antimicrob Chemother; 2007 Dec; 60(6):1302-9. PubMed ID: 17913722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents.
    Nikolaou M; Schilling AN; Vo G; Chang KT; Tam VH
    Ann Biomed Eng; 2007 Aug; 35(8):1458-70. PubMed ID: 17431788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
    Solak S; Willke A; Ergönül O; Tekeli E
    Int J Antimicrob Agents; 2005 Feb; 25(2):181-2. PubMed ID: 15664492
    [No Abstract]   [Full Text] [Related]  

  • 6. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
    Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Apr; 42(4):953-5. PubMed ID: 9559819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa.
    Masuda N; Ohya S
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1847-51. PubMed ID: 1416876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia.
    García-Rodríguez JA; García Sánchez JE; Muñoz Bellido JL; García Sánchez E; García García MI
    J Chemother; 1991 Jun; 3(3):143-6. PubMed ID: 1919651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in susceptibility of Pseudomonas aeruginosa to gatifloxacin and carbapenem in an in vitro urinary bladder model.
    Takahashi S; Hirose T; Sano M; Nishimura M; Matsukawa M; Mikami M; Tsukamoto T
    Chemotherapy; 2000; 46(3):204-8. PubMed ID: 10765037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenemase-producing Pseudomonas aeruginosa in UK.
    Woodford N; Palepou MF; Babini GS; Bates J; Livermore DM
    Lancet; 1998 Aug; 352(9127):546-7. PubMed ID: 9716067
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
    Watanabe Y; Fujiue Y; Yano S; Shimizu S; Muroki K; Doi M; Kuwabara M
    Jpn J Antibiot; 2006 Apr; 59(2):65-71. PubMed ID: 16805317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains.
    Drulis-Kawa Z; Gubernator J; Dorotkiewicz-Jach A; Doroszkiewicz W; Kozubek A
    Int J Pharm; 2006 Jun; 315(1-2):59-66. PubMed ID: 16551496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.
    Ermertcan S; Hoşgör M; Tünger O; Coşar G
    Scand J Infect Dis; 2001; 33(11):818-21. PubMed ID: 11760161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
    Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
    J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Performance evaluation of VITEK 2 system in meropenem susceptibility testing of clinical Pseudomonas aeruginosa isolates].
    Acuner IC; Bayramoğlu G; Birinci A; Cekiç Cihan C; Bek Y; Durupınar B
    Mikrobiyol Bul; 2011 Jul; 45(3):411-21. PubMed ID: 21935774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):157-63. PubMed ID: 9327242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling time-kill studies to discern the pharmacodynamics of meropenem.
    Tam VH; Schilling AN; Nikolaou M
    J Antimicrob Chemother; 2005 May; 55(5):699-706. PubMed ID: 15772138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.
    Louie A; Liu W; VanGuilder M; Neely MN; Schumitzky A; Jelliffe R; Fikes S; Kurhanewicz S; Robbins N; Brown D; Baluya D; Drusano GL
    J Infect Dis; 2015 Apr; 211(8):1326-33. PubMed ID: 25362196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.